Apellis Pharmaceuticals Total Current Liabilities

Apellis Pharmaceuticals (APLS) currently reports a total current liabilities of $280M as of March 2026. That compares with $180M in the prior-year period — up 58.9% year over year. Use the charts on this page to explore Apellis Pharmaceuticals's total current liabilities history and peer comparisons.

Apellis Pharmaceuticals's total current liabilities increased from $180M to $280M — a 58.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Apellis Pharmaceuticals reported $280M in total current liabilities as of March 2026. That compares with $180M in the prior-year period — up 58.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $280M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Apellis Pharmaceuticals, and consider following APLS for alerts when major investors trade the stock.

Apellis Pharmaceuticals is classified in the Healthcare sector. On total current liabilities, it currently shows $280M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing APLS with unrelated industries.